Elacestrant Impresses in EMERALD Trial of Breast Cancer
4.5 (166) · $ 11.50 · In stock
Novel Selective Estrogen Receptor Degraders in Advanced Breast Cancer Use of Elacestrant in the Phase III EMERALD Trial - The ASCO Post
How are people with liver mets doing? - Page 654 — Breastcancer.org
Elacestrant Improves Outcomes for Certain Patients With Breast Cancer
The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes
Dr. O'Shaughnessy on Key Results From the EMERALD Trial in HR+/HER2- Breast Cancer
EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer
Clinical Trials for Metastatic HER2-positive Breast Cancer
Pipeline Report 2022: Patient experience takes center stage
Cancer.Net Podcast – Podcast – Podtail
ASCO Breast Cancer Session 2021: Panel Discussion
